SCMP Insider Trading Activity and SEC Form 4 Filings
SCMP insider trading summary
No open-market insider purchases or sales of Sucampo Pharmaceuticals, Inc. (SCMP) have been reported on SEC Form 4 in the past 12 months.
Latest SCMP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 7, 2017 | Peter A Kiener | Chief Science Officer | Sell | $825K (50,000 @ $16.50) |
| Sep 11, 2017 | Ryuji Ueno | 10% Owner | Sell | $12.0M (1,000,000 @ $12.00) |
| Sep 11, 2017 | Sachiko Kuno | 10% Owner | Sell | $12.0M (1,000,000 @ $12.00) |
| Sep 6, 2017 | Jason Patrick Meyenburg | Chief Commercial Officer | Buy | $49K (4,000 @ $12.13) |
| Aug 4, 2017 | Jones W. Bryan | Sr. Vice Pres., BD & Licensing | Buy | $50K (4,700 @ $10.60) |
| Nov 29, 2016 | Peter Greenleaf | CEO | Sell | $1.4M (82,459 @ $16.75) |
| Nov 29, 2016 | Daniel P Getman | Director | Sell | $64K (3,799 @ $16.75) |
| Nov 28, 2016 | Matthias Alder | EVP, Bus. Dev.&Lic, G.C. &Sec. | Sell | $418K (24,975 @ $16.73) |
| Nov 28, 2016 | Peter Greenleaf | CEO | Sell | $2.0M (117,541 @ $16.91) |
| Nov 28, 2016 | Daniel P Getman | Director | Sell | $274K (16,201 @ $16.89) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.